Clinical efficacy of hypofractionated radiotherapy for patients with locally advanced or advanced non-small cell lung cancer / 中华放射肿瘤学杂志
Chinese Journal of Radiation Oncology
; (6): 1002-1006, 2021.
Article
в Zh
| WPRIM
| ID: wpr-910504
Ответственная библиотека:
WPRO
ABSTRACT
Objective:
To evaluate the survival outcome and toxicity of hypofractionated radiotherapy (45 Gy/15f) in patients with locally advanced/advanced non-small cell lung cancer (NSCLC) who are ineligible for conventional fractionated radiotherapy.Methods:
The early efficacy, survival and toxicity of inoperable patients ( n=64) with locally advanced/advanced NSCLC patients admitted to Cancer Hospital of Tianjin Medical University from 2014 to 2018 were retrospectively analyzed. Hypofractionated radiotherapy (45 Gy/15f) were performed by using intensity-modulated radiotherapy or volumetric-modulated arc therapy technologies on Pinnacle 9 planning system.Results:
The median follow-up time was 26 months. The early efficacy was available in 58 patients complete response for 2 cases (3%), partial response for 22(38%), stable disease for 28(44%) and progressive disease for 6(9%), respectively. The local control rate was 90%. The median time to progression (TTP) and the median overall survival (OS) for all patients was 8.2 months and 21.0 months, respectively. The 1-, 2-and 3-year TTP rate was 37%, 28%, 14% and the OS rate was 66%, 43% and 27%, respectively. The incidence of esophagitis was 17%( n=11), 19%( n=12) for radiation pneumonitis and 20%( n=13) for myelosuppression. No grade ≥3 esophagitis or pneumonia was found.Conclusion:
Hypofractionated radiotherapy (45 Gy/15f) is efficacious and safe for patients with locally advanced/advanced NSCLC, which yields controllable adverse events.
Полный текст:
1
База данных:
WPRIM
Язык:
Zh
Журнал:
Chinese Journal of Radiation Oncology
Год:
2021
Тип:
Article